




RealRate

PHARMACEUTICAL 2022

Arrowhead Pharmaceuticals INC
Rank 267 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Arrowhead Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arrowhead Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Arrowhead Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is 267%, being 8.5% points below the market average of 275%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	384,597	Assets	710,148
Cost of Goods Sold	0	Liabilities	301,326
Intangible Assets	13,663	Expenses	287,325
Liabilities, Current	146,536	Revenues	138,287
Liabilities, Non-Current	154,790	Stockholders Equity	408,822
Other Assets	263,213	Net Income	-140,848
Other Compr. Net Income	-87	Comprehensive Net Income	-140,892
Other Expenses	2.0	BaseVar	722,682
Other Liabilities	0	ECR before LimitedLiability	148%
Other Net Income	8,190	Economic Capital Ratio	267%
Other Revenues	138,287		
Property and Equipment	48,675		
Research and Development	206,342		
Selling, General and Administrative Expense	80,981		